Welcome to our dedicated page for Danaher Corporation news (Ticker: DHR), a resource for investors and traders seeking the latest updates and insights on Danaher Corporation stock.
Danaher Corporation (NYSE: DHR) is a globally diversified conglomerate based in Washington, D.C., focusing primarily on life sciences and diagnostics. Founded in 1984 by Stephen and Mitchell Rales, the company has transitioned from a real estate organization into a leading player in the medical, industrial, and commercial products sectors.
Danaher designs, manufactures, and markets a variety of innovative products, particularly scientific instruments and consumables. The company has recently revamped its portfolio by divesting its environmental and applied solutions group, Veralto, in late 2023. This strategic move has allowed Danaher to concentrate its efforts on advancing health through science and technology.
Among Danaher's notable achievements is the acquisition of Abcam plc, which enhances its capabilities in proteomics—an expanding field within life sciences. The company is also known for its contribution to gene-editing therapies through a collaboration with the Innovative Genomics Institute (IGI), aiming to develop CRISPR-based treatments for various diseases.
Danaher's portfolio includes well-known subsidiaries like Beckman Coulter Life Sciences, Integrated DNA Technologies, and Aldevron. These subsidiaries focus on delivering innovative solutions in diagnostics, genomics, and biomanufacturing. For instance, Beckman Coulter's recent partnership with Curiox Biosystems aims to provide automated sample preparation for flow cytometry, enhancing research efficiency.
Financially, Danaher reported better-than-expected revenue in the fourth quarter of 2023, bolstered by strong performance in its life sciences and diagnostics segments. The company's strategic divestitures and acquisitions have positioned it for long-term growth and increased shareholder value.
Danaher’s ongoing projects include a collaboration with Cincinnati Children's Hospital to improve liver organoid technology for drug toxicity screening. This initiative is part of the Danaher Beacons program, which funds pioneering academic research to develop next-generation medical technologies. Another significant collaboration is with Johns Hopkins University, focusing on diagnosing mild traumatic brain injuries (TBI) using advanced biomarker panels.
Overall, Danaher's commitment to scientific excellence, innovation, and continuous improvement makes it a crucial player in advancing healthcare globally. With over 63,000 associates worldwide, Danaher is dedicated to improving quality of life and laying the groundwork for a healthier, more sustainable future.
Danaher Corporation (NYSE: DHR) will conduct a live video webcast of its Investor and Analyst Meeting on September 9, 2021, starting at 12:00 p.m. ET. The event features President and CEO Rainer M. Blair and will be accessible via Danaher's website under the 'Investors' section. Attendees can find a link to the webcast and accompanying slides, while a replay will be available post-presentation. Danaher specializes in science and technology innovation, focusing on health care, environmental, and applied markets.
Danaher Corporation (NYSE: DHR) announced significant leadership changes effective April 1, 2022. Georgeann F. Couchara will succeed Angela S. Lalor as Senior Vice President of Human Resources, while Christopher M. Bouda will take over as Chief Accounting Officer from Robert S. Lutz on January 1, 2022. Both transitions aim to enhance the company's strategic focus on talent and finance. Lalor and Lutz will support the transition in advisory roles until their retirements in 2023 and 2022, respectively. Danaher emphasizes its commitment to fostering a robust leadership pipeline.
Danaher Corporation (NYSE: DHR) announced the passing of former President & CEO George M. Sherman, who led the company from 1990 to 2001. During his tenure, Danaher's sales grew five-fold and market capitalization increased over 20 times, primarily through strategic acquisitions. Sherman transformed Danaher into a focused global corporation and established the Danaher Business System as its operating philosophy. Chairman Steven M. Rales expressed deep condolences and highlighted Sherman's lasting influence on the company.
Danaher Corporation (NYSE: DHR) announced a significant investment plan from its subsidiaries, Cytiva and Pall Corporation, totaling 1.5 billion USD over the next two years. This investment will enhance manufacturing capacity for key products used in biologic medicines across multiple geographies, including the US, UK, Austria, China, and other regions. Specific allocations include 600 million USD for chromatography resins, 400 million USD for cell culture media, and 300 million USD for single-use technologies. The initiative aims to address supply chain challenges and improve overall manufacturing agility.
Beckman Coulter has finalized agreements with Quidel Corporation to acquire rights for the BNP assay, previously sold as TRIAGE® BNP. Beckman Coulter will exclusively manufacture and market the Access BNP assay, transitioning distribution from Quidel globally. The agreements resolve ongoing litigation and disputes between the two companies. This addition expands Beckman Coulter's cardiovascular diagnostic offerings, crucial for managing cardiovascular diseases, which account for 31% of global deaths. The Access BNP assay aids in diagnosing heart failure, enhancing patient care.
Danaher Corporation (NYSE: DHR) reported strong financial results for Q2 2021, achieving net earnings of $1.7 billion, a remarkable 84% increase year-over-year. Diluted earnings per share reached $2.28, with non-GAAP adjusted earnings at $2.46, up 71%. Revenues surged to $7.2 billion, reflecting a 36.5% year-over-year growth. Operating cash flow rose by 46.5% to $2.1 billion, and free cash flow increased by 41% to $1.8 billion. For Q3 2021, Danaher forecasts mid- to high-teens percent non-GAAP core revenue growth and a full-year estimate of approximately 20% growth.
Danaher Corporation (NYSE: DHR) will host its quarterly earnings conference call for the second quarter of 2021 on July 22, 2021, at 8:00 a.m. ET. The call will last approximately one hour and will be available for live streaming on the company's website. A replay will be accessible shortly after the call until August 5, 2021. Pre-call dial-in is available for U.S. and international participants. Earnings materials will be posted on Danaher’s investor section starting at 6:00 a.m. ET on the day of the call.
SCIEX launches the ZenoTOF 7600 system, an advanced mass LC-MS/MS instrument, enhancing the identification and quantification of biomolecules. This system promises up to 20x greater sensitivity and can quantify 40% more proteins than previous models while analyzing samples 5x faster. The integrated Zeno trap and electron activated dissociation (EAD) fragmentation enable researchers to explore post-translational modifications and biomarker discovery effectively, pushing boundaries in precision diagnostics and biopharmaceutical development.
SCIEX has enhanced its software portfolio, launching the OneOmics suite, which facilitates big data processing in multi-omics research via secure cloud computing. This suite allows researchers to analyze large proteomics and metabolomics datasets significantly faster. Additionally, the Molecule Profiler app aids in identifying and quantifying biopharmaceutical metabolites and impurities. The SCIEX OS software ecosystem, now supporting the ZenoTOF 7600 system, ensures data integrity and streamlines workflows for scientists across multiple labs.
Danaher Corporation (NYSE: DHR) announced its agreement to acquire Aldevron for approximately $9.6 billion, enhancing Danaher's presence in genomic medicine. Aldevron, founded in 1998, specializes in high-quality plasmid DNA, mRNA, and proteins, and will operate as a standalone entity within Danaher’s Life Sciences segment. The acquisition aims to support the development of cell, gene therapies, and vaccines. The transaction is subject to customary regulatory approvals.
FAQ
What is the current stock price of Danaher Corporation (DHR)?
What is the market cap of Danaher Corporation (DHR)?
What does Danaher Corporation specialize in?
Who founded Danaher Corporation and when?
Where is Danaher Corporation headquartered?
What recent divestiture has Danaher Corporation made?
What are some of Danaher's notable subsidiaries?
What recent acquisition has enhanced Danaher's capabilities in proteomics?
What is the Danaher Beacons program?
What collaboration is Danaher involved in to improve liver organoid technology?
What is the focus of Danaher's partnership with Johns Hopkins University?
How does Danaher contribute to the field of gene-editing therapies?
